Cite
HARVARD Citation
Nishimoto, K. et al. (2022). Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib. IJU case reports. 5 (3), pp. 149-152. [Online].